These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27664062)

  • 21. Accuracy and Injection Force of the Gla-300 Injection Device Compared With Other Commercialized Disposable Insulin Pens.
    Klonoff D; Nayberg I; Thonius M; See F; Abdel-Tawab M; Erbstein F; Haak T
    J Diabetes Sci Technol; 2015 Aug; 10(1):125-30. PubMed ID: 26311720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label study.
    Haak T; Edelman S; Walter C; Lecointre B; Spollett G
    Clin Ther; 2007 Apr; 29(4):650-60. PubMed ID: 17617288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ease of use and patient preference injection simulation study comparing two prefilled insulin pens.
    Clark PE; Valentine V; Bodie JN; Sarwat S
    Curr Med Res Opin; 2010 Jul; 26(7):1745-53. PubMed ID: 20482243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of glargine insulin delivery method (pen device versus vial/syringe) on glycemic control and patient preferences in patients with type 1 and type 2 diabetes.
    Seggelke SA; Hawkins RM; Gibbs J; Rasouli N; Wang CC; Draznin B
    Endocr Pract; 2014 Jun; 20(6):536-9. PubMed ID: 24326004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and safety of basal supported oral therapy with insulin glargine, in Japanese insulin-naive, type 2 diabetes patients, with or without microvascular complications: subanalysis of the observational, non-interventional, 24-week follow-up Add-on Lantus® to Oral Hypoglycemic Agents (ALOHA) study.
    Odawara M; Kadowaki T; Naito Y
    J Diabetes Complications; 2015; 29(1):127-33. PubMed ID: 25449981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Healthcare professional and patient assessment of a new prefilled insulin pen versus two widely available prefilled insulin pens for ease of use, teaching and learning.
    Nadeau DA; Campos C; Niemeyer M; Bailey T
    Curr Med Res Opin; 2012 Jan; 28(1):3-13. PubMed ID: 22114905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dosing accuracy with a novel pen device (SoloSTAR) as performed by patients with diabetes in a clinical setting.
    Hermanns N; Kulzer B; Haak T
    Diabetes Technol Ther; 2008 Aug; 10(4):322-7. PubMed ID: 18715206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment for ease of use and preference of a new prefilled insulin pen (FlexTouch Degludec U100/U200) versus the SoloSTAR insulin pen by patients with diabetes and healthcare professionals.
    Pfützner A; Forst T; Niemeyer M; Bailey T
    Expert Opin Drug Deliv; 2014 Sep; 11(9):1381-9. PubMed ID: 24921223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial.
    Davies MJ; Russell-Jones D; Selam JL; Bailey TS; Kerényi Z; Luo J; Bue-Valleskey J; Iványi T; Hartman ML; Jacobson JG; Jacober SJ;
    Diabetes Obes Metab; 2016 Nov; 18(11):1055-1064. PubMed ID: 27349219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2 diabetes: results of the phase IV COBALTA trial.
    Perez A; Carrasco-Sánchez FJ; González C; Seguí-Ripoll JM; Trescolí C; Ena J; Borrell M; Gomez Huelgas R
    BMJ Open Diabetes Res Care; 2020 Sep; 8(1):. PubMed ID: 32928792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Needle-free jet injection of insulin glargine improves glycemic control in patients with type 2 diabetes mellitus: a study based on the flash glucose monitoring system.
    Kong X; Luo M; Cai L; Zhang P; Yan R; Hu Y; Li H; Ma J
    Expert Opin Drug Deliv; 2021 May; 18(5):635-641. PubMed ID: 33317342
    [No Abstract]   [Full Text] [Related]  

  • 32. Usability, participant acceptance, and safety of a prefilled insulin injection device in a 3-month observational survey in everyday clinical practice in Australia.
    Carter J; Beilin J; Morton A; De Luise M
    J Diabetes Sci Technol; 2009 Nov; 3(6):1425-38. PubMed ID: 20144398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An analysis of patient acceptance and safety of a prefilled insulin injection device.
    Kroon L
    J Diabetes Sci Technol; 2009 Nov; 3(6):1439-41. PubMed ID: 20144399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usability of a pre-filled insulin injection device in a 3-month observational survey of everyday clinical practice in Australia.
    Carter J; Roberts A
    Curr Med Res Opin; 2008 Oct; 24(10):2741-9. PubMed ID: 18715525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen.
    Bergenstal RM; Peyrot M; Dreon DM; Aroda VR; Bailey TS; Brazg RL; Frias JP; Johnson ML; Klonoff DC; Kruger DF; Ramtoola S; Rosenstock J; Serusclat P; Weinstock RS; Naik RG; Shearer DM; Zraick V; Levy BL;
    Diabetes Technol Ther; 2019 May; 21(5):273-285. PubMed ID: 31025878
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of simplicity, convenience, safety, and cost-effectiveness between use of insulin pen devices and disposable plastic syringes by patients with type 2 diabetes mellitus: a cross-sectional study from Bangladesh.
    Kamrul-Hasan ABM; Hannan MA; Alam MS; Rahman MM; Asaduzzaman M; Mustari M; Paul AK; Kabir ML; Chowdhury SR; Talukder SK; Sarkar S; Hannan MA; Islam MR; Iftekhar MH; Robel MAB; Selim S
    BMC Endocr Disord; 2023 Feb; 23(1):37. PubMed ID: 36782190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal-Bolus Insulin: Phase 4 OPTIMIZE Study.
    Mathieu C; Weisnagel SJ; Stella P; Bruhwyler J; Alexandre K
    Diabetes Ther; 2020 Feb; 11(2):495-507. PubMed ID: 31925722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study Protocol for a Prospective, Multicenter, Randomized, Open-Label, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of a Needle-Free Insulin Injector and a Conventional Insulin Pen in Controlling Blood Glucose Concentrations in Chinese Patients with Type 2 Diabetes Mellitus (The FREE Study).
    Ji L; Chen L; Wang Y; Ma Z; Ran X; Sun Z; Xu X; Wang G; Guo L; Shan Z
    Adv Ther; 2019 Jun; 36(6):1485-1496. PubMed ID: 31004325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL (Gla-300) in Brazilian people with type 1 diabetes.
    Dualib PM; Dib SA; Augusto GA; Truzzi AC; de Paula MA; Réa RR
    Diabetol Metab Syndr; 2024 Jul; 16(1):152. PubMed ID: 38982528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Uncontrolled on Basal Insulin: The 26-Week Interventional, Single-Arm ARTEMIS-DM Study.
    Sethi B; Al-Rubeaan K; Unubol M; Mabunay MA; Berthou B; Pilorget V; Vethakkan SR; Frechtel G
    Diabetes Ther; 2022 Jul; 13(7):1395-1408. PubMed ID: 35713873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.